This site is intended for healthcare professionals
Drug news

Phase II/III trial of RGN 259 (thymosin beta 4) for the treatment of dry eye fails to meet endpoint-RegeneRx Biopharmaceuticals

Read time: 1 mins
Last updated:7th May 2016
Published:7th May 2016
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest